Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron bets added cholesterol benefit will help its obesity drug stand out
12:42pm, Friday, 30'th Jan 2026
Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly cro
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say
11:32am, Friday, 30'th Jan 2026
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics comp
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
11:25am, Friday, 30'th Jan 2026
REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.
Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory
10:56am, Friday, 30'th Jan 2026
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71.
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
08:41am, Friday, 30'th Jan 2026
Regeneron (REGN) came out with quarterly earnings of $11.44 per share, beating the Zacks Consensus Estimate of $10.56 per share. This compares to earnings of $12.07 per share a year ago.
First Look: Fed pick, Apple iPhone boom, Tesla pivot, metals swing
07:39am, Friday, 30'th Jan 2026
Stock News Warsh tapped for Fed: U.S. markets (SPY) steadied after President Donald Trump named former governor Kevin Warsh to succeed Jerome Powell as Federal
Regeneron beats quarterly profit estimates on Dupixent strength
07:37am, Friday, 30'th Jan 2026
U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
06:30am, Friday, 30'th Jan 2026
TARRYTOWN, N.Y., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business up
Bank of New York Mellon Corp Acquires 15,006 Shares of Regeneron Pharmaceuticals, Inc. $REGN
04:18am, Friday, 30'th Jan 2026
Bank of New York Mellon Corp lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 2.3% in the undefined quarter, according to its most recent Form 13F filing with the Securities an
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?
10:16am, Wednesday, 28'th Jan 2026
REGN's Q4 report could hinge on Dupixent profit growth and strong Eylea HD uptake as legacy Eylea sales face competitive pressure.
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cullen Frost Bankers Inc.
05:10am, Wednesday, 28'th Jan 2026
Cullen Frost Bankers Inc. trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 91.9% during the third quarter, according to its most recent filing with the Securities and Exchange Co
Evergreen Wealth Management LLC Sells 808 Shares of Regeneron Pharmaceuticals, Inc. $REGN
06:04am, Tuesday, 27'th Jan 2026
Evergreen Wealth Management LLC reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 7.7% in the undefined quarter, according to its most recent Form 13F filing with the
General American Investors Co. Inc. Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN
05:22am, Tuesday, 27'th Jan 2026
General American Investors Co. Inc. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 217.6% during the undefined quarter, according to its most recent disclosure with the Securities
Compass Wealth Management LLC Buys Shares of 3,634 Regeneron Pharmaceuticals, Inc. $REGN
04:48am, Tuesday, 27'th Jan 2026
Compass Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the third quarter, according to the company in its most recent Form 13F filing wit
